Research ExplorerPublicationsDemographics, Clinical Characteristics and Survival Outcomes...

Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis

Standard

Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis. / Morra, Simone; Incesu, Reha-Baris; Scheipner, Lukas; Baudo, Andrea; Jannello, Letizia Maria Ippolita; de Angelis, Mario; Siech, Carolin; Goyal, Jordan A; Tian, Zhe; Saad, Fred; Califano, Gianluigi; la Rocca, Roberto; Capece, Marco; Shariat, Shahrokh F; Ahyai, Sascha; Carmignani, Luca; de Cobelli, Ottavio; Musi, Gennaro; Tilki, Derya; Briganti, Alberto; Chun, Felix K H; Longo, Nicola; Karakiewicz, Pierre I.

In: CANCERS, Vol. 15, No. 18, 4498, 10.09.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Morra, S, Incesu, R-B, Scheipner, L, Baudo, A, Jannello, LMI, de Angelis, M, Siech, C, Goyal, JA, Tian, Z, Saad, F, Califano, G, la Rocca, R, Capece, M, Shariat, SF, Ahyai, S, Carmignani, L, de Cobelli, O, Musi, G, Tilki, D, Briganti, A, Chun, FKH, Longo, N & Karakiewicz, PI 2023, 'Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis', CANCERS, vol. 15, no. 18, 4498. https://doi.org/10.3390/cancers15184498

APA

Morra, S., Incesu, R-B., Scheipner, L., Baudo, A., Jannello, L. M. I., de Angelis, M., Siech, C., Goyal, J. A., Tian, Z., Saad, F., Califano, G., la Rocca, R., Capece, M., Shariat, S. F., Ahyai, S., Carmignani, L., de Cobelli, O., Musi, G., Tilki, D., ... Karakiewicz, P. I. (2023). Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis. CANCERS, 15(18), [4498]. https://doi.org/10.3390/cancers15184498

Vancouver

Morra S, Incesu R-B, Scheipner L, Baudo A, Jannello LMI, de Angelis M et al. Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis. CANCERS. 2023 Sep 10;15(18). 4498. https://doi.org/10.3390/cancers15184498

Bibtex

@article{50798b9e5ad049a1b1675caef2d08825,
title = "Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis",
abstract = "All primary urinary tract malignant melanoma (ureter vs. bladder vs. urethra) patients were identified from within the Surveillance, Epidemiology, and End Results (SEER) database 2000-2020. Kaplan-Maier plots depicted the overall survival (OS) rates. Univariable and multivariable Cox regression (MCR) models were fitted to test the differences in overall mortality (OM). In the overall cohort (n = 74), the median OS was 22 months. No statistically significant or clinically meaningful differences were recorded according to sex (female vs. male; p = 0.9) and treatment of the primary (endoscopic vs. surgical; p = 0.6). Conversely, clinically meaningful but not statistically significant (p ≥ 0.05) differences were recorded according to the patient's age at diagnosis (≤80 vs. ≥80 years old; p = 0.2), marital status (married 26 vs. unmarried 16 months; p = 0.2), and SEER stage (localized 31 vs. regional 14 months; p = 0.4), and the type of systemic therapy (exposed 31 vs. not exposed 20 months; p = 0.06). Finally, in univariable and MCR analyses, after adjustment for the SEER stage and type of systemic therapy, tumor origin within the bladder was associated with a three-fold higher OM (Hazard ratio: 3.00; p = 0.004), compared to tumor origin within the urethra. In conclusion, primary urinary tract malignant melanoma patients have poor survival. Specifically, tumor origin within the bladder independently predicted a higher OM, even after adjustment for the SEER stage and systemic therapy status.",
author = "Simone Morra and Reha-Baris Incesu and Lukas Scheipner and Andrea Baudo and Jannello, {Letizia Maria Ippolita} and {de Angelis}, Mario and Carolin Siech and Goyal, {Jordan A} and Zhe Tian and Fred Saad and Gianluigi Califano and {la Rocca}, Roberto and Marco Capece and Shariat, {Shahrokh F} and Sascha Ahyai and Luca Carmignani and {de Cobelli}, Ottavio and Gennaro Musi and Derya Tilki and Alberto Briganti and Chun, {Felix K H} and Nicola Longo and Karakiewicz, {Pierre I}",
year = "2023",
month = sep,
day = "10",
doi = "10.3390/cancers15184498",
language = "English",
volume = "15",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "18",

}

RIS

TY - JOUR

T1 - Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis

AU - Morra, Simone

AU - Incesu, Reha-Baris

AU - Scheipner, Lukas

AU - Baudo, Andrea

AU - Jannello, Letizia Maria Ippolita

AU - de Angelis, Mario

AU - Siech, Carolin

AU - Goyal, Jordan A

AU - Tian, Zhe

AU - Saad, Fred

AU - Califano, Gianluigi

AU - la Rocca, Roberto

AU - Capece, Marco

AU - Shariat, Shahrokh F

AU - Ahyai, Sascha

AU - Carmignani, Luca

AU - de Cobelli, Ottavio

AU - Musi, Gennaro

AU - Tilki, Derya

AU - Briganti, Alberto

AU - Chun, Felix K H

AU - Longo, Nicola

AU - Karakiewicz, Pierre I

PY - 2023/9/10

Y1 - 2023/9/10

N2 - All primary urinary tract malignant melanoma (ureter vs. bladder vs. urethra) patients were identified from within the Surveillance, Epidemiology, and End Results (SEER) database 2000-2020. Kaplan-Maier plots depicted the overall survival (OS) rates. Univariable and multivariable Cox regression (MCR) models were fitted to test the differences in overall mortality (OM). In the overall cohort (n = 74), the median OS was 22 months. No statistically significant or clinically meaningful differences were recorded according to sex (female vs. male; p = 0.9) and treatment of the primary (endoscopic vs. surgical; p = 0.6). Conversely, clinically meaningful but not statistically significant (p ≥ 0.05) differences were recorded according to the patient's age at diagnosis (≤80 vs. ≥80 years old; p = 0.2), marital status (married 26 vs. unmarried 16 months; p = 0.2), and SEER stage (localized 31 vs. regional 14 months; p = 0.4), and the type of systemic therapy (exposed 31 vs. not exposed 20 months; p = 0.06). Finally, in univariable and MCR analyses, after adjustment for the SEER stage and type of systemic therapy, tumor origin within the bladder was associated with a three-fold higher OM (Hazard ratio: 3.00; p = 0.004), compared to tumor origin within the urethra. In conclusion, primary urinary tract malignant melanoma patients have poor survival. Specifically, tumor origin within the bladder independently predicted a higher OM, even after adjustment for the SEER stage and systemic therapy status.

AB - All primary urinary tract malignant melanoma (ureter vs. bladder vs. urethra) patients were identified from within the Surveillance, Epidemiology, and End Results (SEER) database 2000-2020. Kaplan-Maier plots depicted the overall survival (OS) rates. Univariable and multivariable Cox regression (MCR) models were fitted to test the differences in overall mortality (OM). In the overall cohort (n = 74), the median OS was 22 months. No statistically significant or clinically meaningful differences were recorded according to sex (female vs. male; p = 0.9) and treatment of the primary (endoscopic vs. surgical; p = 0.6). Conversely, clinically meaningful but not statistically significant (p ≥ 0.05) differences were recorded according to the patient's age at diagnosis (≤80 vs. ≥80 years old; p = 0.2), marital status (married 26 vs. unmarried 16 months; p = 0.2), and SEER stage (localized 31 vs. regional 14 months; p = 0.4), and the type of systemic therapy (exposed 31 vs. not exposed 20 months; p = 0.06). Finally, in univariable and MCR analyses, after adjustment for the SEER stage and type of systemic therapy, tumor origin within the bladder was associated with a three-fold higher OM (Hazard ratio: 3.00; p = 0.004), compared to tumor origin within the urethra. In conclusion, primary urinary tract malignant melanoma patients have poor survival. Specifically, tumor origin within the bladder independently predicted a higher OM, even after adjustment for the SEER stage and systemic therapy status.

U2 - 10.3390/cancers15184498

DO - 10.3390/cancers15184498

M3 - SCORING: Journal article

C2 - 37760467

VL - 15

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 18

M1 - 4498

ER -